---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104092"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T18:51:08.275511+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Acadia Q2 revenue $264.6M (+9% YoY); NUPLAZID guidance raised to $665-690M

## Summary
- Total revenue $264.6M, NUPLAZID $168.5M (+7%), DAYBUE $96.1M (+14%).
- Net income $26.7M ($0.16 EPS) vs $33.4M ($0.20 EPS) YoY due to higher tax rate.
- Raised NUPLAZID net sales guidance low end to $665M; total revenue guidance $1.045-1.095B.
- Patent litigation wins affirm NUPLAZID exclusivity through 2030 (composition) and 2038 (formulation).
- COMPASS PWS Phase 3 study enrollment complete; top-line results expected early Q4 2025.

## SEC filing metadata
- accession: 0000950170-25-104092
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000095017025104092/0000950170-25-104092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000095017025104092/acad-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104092
- JSON: https://secwatch.observer/filing/0000950170-25-104092.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.